IRLAB A Stock Overview
IRLAB Therapeutics AB (publ) develops drugs for the treatment of Parkinson’s disease.
IRLAB Therapeutics AB (publ) Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||kr33.35|
|52 Week High||kr63.00|
|52 Week Low||kr28.55|
|1 Month Change||-6.32%|
|3 Month Change||-7.75%|
|1 Year Change||-45.77%|
|3 Year Change||-19.93%|
|5 Year Change||19.96%|
|Change since IPO||182.63%|
Recent News & Updates
We Like IRLAB Therapeutics' (STO:IRLAB A) Earnings For More Than Just Statutory Profit
Shareholders appeared to be happy with IRLAB Therapeutics AB (publ)'s ( STO:IRLAB A ) solid earnings report last week...
|IRLAB A||SE Pharmaceuticals||SE Market|
Return vs Industry: IRLAB A underperformed the Swedish Pharmaceuticals industry which returned -18.1% over the past year.
Return vs Market: IRLAB A underperformed the Swedish Market which returned -21.8% over the past year.
|IRLAB A volatility|
|IRLAB A Average Weekly Movement||5.3%|
|Pharmaceuticals Industry Average Movement||7.8%|
|Market Average Movement||7.2%|
|10% most volatile stocks in SE Market||12.6%|
|10% least volatile stocks in SE Market||4.5%|
Stable Share Price: IRLAB A is less volatile than 75% of Swedish stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: IRLAB A's weekly volatility (5%) has been stable over the past year.
About the Company
IRLAB Therapeutics AB (publ) develops drugs for the treatment of Parkinson’s disease. The company develops Mesdopetam that is in phase IIb/III clinical studies for the treatment of dyskinesia; and Pirepemat, which is in phase IIb clinical trial for the treatment of Postural dysfunction. Its preclinical stage products include IRL942 and 1009 research programs for the treatment of neurodegenerative disorders and ageing; and IRL757 to treat apathy in neurological diseases.
IRLAB Therapeutics AB (publ) Fundamentals Summary
|IRLAB A fundamental statistics|
Is IRLAB A overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IRLAB A income statement (TTM)|
|Cost of Revenue||kr95.73m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Aug 24, 2022
|Earnings per share (EPS)||0.82|
|Net Profit Margin||19.66%|
How did IRLAB A perform over the long term?See historical performance and comparison